GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (STU:I76) » Definitions » Shiller PE Ratio

Ironwood Pharmaceuticals (STU:I76) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ironwood Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ironwood Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Ironwood Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals Shiller PE Ratio Chart

Ironwood Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ironwood Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ironwood Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ironwood Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's Shiller PE Ratio falls into.



Ironwood Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ironwood Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ironwood Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.028/131.7762*131.7762
=-0.028

Current CPI (Mar. 2024) = 131.7762.

Ironwood Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.324 100.560 -0.425
201409 -0.233 100.428 -0.306
201412 -0.219 99.070 -0.291
201503 -0.222 99.621 -0.294
201506 -0.303 100.684 -0.397
201509 -0.294 100.392 -0.386
201512 -0.083 99.792 -0.110
201603 -0.081 100.470 -0.106
201606 -0.134 101.688 -0.174
201609 -0.205 101.861 -0.265
201612 -0.085 101.863 -0.110
201703 -0.337 102.862 -0.432
201706 -0.267 103.349 -0.340
201709 -0.185 104.136 -0.234
201712 0.068 104.011 0.086
201803 -0.235 105.290 -0.294
201806 -0.274 106.317 -0.340
201809 -0.977 106.507 -1.209
201812 -0.088 105.998 -0.109
201903 -0.336 107.251 -0.413
201906 0.071 108.070 0.087
201909 0.118 108.329 0.144
201912 0.270 108.420 0.328
202003 0.018 108.902 0.022
202006 0.142 108.767 0.172
202009 0.178 109.815 0.214
202012 0.222 109.897 0.266
202103 0.210 111.754 0.248
202106 1.984 114.631 2.281
202109 0.289 115.734 0.329
202112 0.221 117.630 0.248
202203 0.191 121.301 0.207
202206 0.199 125.017 0.210
202209 0.283 125.227 0.298
202212 0.255 125.222 0.268
202303 0.233 127.348 0.241
202306 -6.313 128.729 -6.462
202309 0.084 129.860 0.085
202312 -0.009 129.419 -0.009
202403 -0.028 131.776 -0.028

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ironwood Pharmaceuticals  (STU:I76) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ironwood Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ironwood Pharmaceuticals (STU:I76) Business Description

Traded in Other Exchanges
Address
100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ironwood Pharmaceuticals (STU:I76) Headlines

No Headlines